GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Policy Acquisition Expense

Relmada Therapeutics (STU:4E2) Policy Acquisition Expense


View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Relmada Therapeutics (STU:4E2) Business Description

Traded in Other Exchanges
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.